Valerio Therapeutics : Transactions on the share capital of Valerio Therapeutics to restructure part of its liabilities

About this update from Valerio Therapeutics

[{"type":"text","content":"\n Previous\n \n Transactions on the share capital of Valerio Therapeutics to restructure part of its liabilitiesTransactions on the share capital of Valerio Therapeutics to restructure part of its liabilities\n Paris (France), 22 July 2025\n \n \n Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereinafter 'Valerio Therapeutics' or the 'Company', announces the completion of several transactions on its share capital with a view to restructure part of its liabilities. The Company's Board of Directors meeting on 21 July 2025 took the following decisions:\n \n \n • Capital reduction motivated by losses through a reduction in the nominal value of shares\n Exercising the delegation granted by the General Meeting of 17 July 2025, the Board of Directors of 21 July 2025 decided to proceed with a capital reduction by clearing part of the losses in the amount of €20,067,355.47. This capital reduction motivated by losses was carried out by reducing the nominal value of the Company's shares from €0.14 to €0.01. This transaction had no impact on the number of shares in circulation. Following this transaction, the Company's share capital amounted to €1,543,642.73, divided into 154,364,273 ordinary shares with a nominal value of €0.01 each.\n \n \n • Conversion of convertible bonds by Financière de la Montagne\n As a reminder, the Board of Directors, exercising the powers delegated to it under the terms of the 13th resolution of the General Meeting of 10 June 2021, decided on 6 April 2022 to issue a convertible bond loan with a nominal value of €4,000,000 through the issue 4,000,000 convertible bonds (the 'CBs') with a nominal value of €1 each and to reserve the subscription to Financière de la Montagne for an amount of 1,500,000 euros. The CBs Issue Agreement was entered into between the Company and Financière de la Montagne on 20 April 2022.\n \n \n Pursuant to the CBs Issue Agreement, the Company sent Financière de la Montagne a notice of exercise of the CBs for the purpose of converting the 1,500,000 CBs it holds into 27,777,777 ordinary shares of the Company with a par value of €0.01 (following the aforementioned capital reduction), at a price of €0.054 calculated in accordance with the CBs Issue Agreement (volume-weighted average price of the last three trading days preceding the exercise of the Convertible Bonds, rounded down ...

More updates from Valerio Therapeutics